36 results
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
introduction of a new topical therapy that is more effective and less toxic than currently available topical drugs (if that is what is shown) would … not reduce the toxic side effects of daunorubicin (including cardiotoxicity) and it failed to qualify a majority of patients for curative bone marrow
8-K
EX-10.1
MBRX
Moleculin Biotech Inc
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment
8-K
EX-10.1
vgyy6ce
25 Jun 21
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-1.1
cgx45j k0
25 Jun 21
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-1.1
p8kvizk w44
4 Feb 21
Moleculin Announces Proposed Underwritten Public Offering
4:07pm
8-K
EX-99.1
1hc01h7
19 Nov 20
Moleculin Announces New Data Demonstrating
4:00pm
8-K
EX-99.1
z3zesr63typfp4 gzh9
21 Oct 20
Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors, Further Supporting IND
7:29am
8-K
EX-1.1
cxx27
17 Jul 20
Entry into a Material Definitive Agreement
5:19pm
8-K
EX-99.1
zkvx2z1ib
25 Jun 20
Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
7:31am
8-K
EX-99.1
jsvfaf3 wl5
8 Apr 20
Other Events
7:30am
8-K
EX-99.1
8q0eky93
16 Mar 20
Regulation FD Disclosure
12:00am
8-K
EX-1.1
2o7z4nz0d1lqxxoqs3
6 Feb 20
Entry into a Material Definitive Agreement
9:06am
8-K
EX-99.1
hh4if m3bd6ajxq
13 Jan 20
Regulation FD Disclosure
7:01am
8-K
EX-99.1
657q by51m1zag5
12 Nov 19
Results of Operations and Financial Condition
6:33am